|

Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma

RECRUITINGSponsored by Guangxi Medical University
Actively Recruiting
SponsorGuangxi Medical University
Started2019-03-03
Est. completion2030-12-18
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted

Summary

Though hepatectomy is one of the curative treatment for patients with hepatocellular carcinoma (HCC), the 5-years recurrence-free survival is lower than 30%. In recent years, several immune checkpoint inhibitors have been approved in advanced HCC. However, no study about the safety and efficacy of adjuvant immune checkpoint inhibitors for patients with HCC after hepatectomy was reported.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Underwent curative hepatectomy;
* Diagnosis of HCC was confirmed by postoperative histopathology;
* Liver function Child-Pugh A or B;
* Performance status score 0 or 1
* With high risk factor of HCC recurrence, such as tumor size ≥ 5 cm, multinodular, macrovascular invasion or microvascular invasion;

Exclusion Criteria:

* Receive neoadjuvant immune checkpoint inhibitors therapy.

Conditions4

CancerHepatocellular CarcinomaLiver CancerLiver Disease

Interventions1

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.